Close
Log-In
|
Home
|
E-mail Alerts
|
My Headlines
|
Portfolio
Give the Gift of Market Intelligence - StreetInsider Premium
Home
Menu
Join Free
SI Premium
Ratings Insider
M&A Insider
EPS Insider
Dividend Insider
IPO Insider
Hedge Fund Insider
Premium Newsletters
Join Free
SI Premium
Full Feed View
Headline View
Upgrade to SI Premium
Ratings Insider
Upgrade News
Downgrade News
New Coverage News
More...
M&A Insider
Merger News
More...
EPS Insider
Earnings News
More...
Dividend Insider
Dividend News
More...
IPO Insider
IPO News
More...
Hedge Fund Insider
Hedge Funds News
More...
Premium Newsletters
QUICK LINKS :
Upcoming Dividends
EPS Movers
Top Upgrades
Buffett's Stocks
FREE SI Newsletters
Google
Follow @Street_Insider
Premium Content
News Feeds
Full Feed $
Today's Headlines
Custom Headlines
My Portfolio Headlines
Entities
Company News
Corporate News
Hot Corp. News $
Litigation
Management Changes
Hot Mgmt Changes $
Retail Sales
Dividends/Sh. Returns
Dividends $
Hot Dividends $
Special Dividends $
Stock Buybacks $
Hot Buybacks $
Stock Splits $
EPS
Conference Calls
Earnings $
Hot Earnings $
Guidance $
Hot Guidance $
ETFs
ETFs
FDA
FDA $
Hot FDA News $
Insiders/Hedge Funds
13Ds $
13Fs $
13Gs $
Hedge Funds $
Hot Hedge Fund News $
Insider Trades $
Hot Insider Trades $
M&A
Mergers and Acquisitions $
Hot M&A $
Private Equity
Rumors $
Macro
Commodities $
Economic Data
Fed
Market Check
Market Movers
Hot List $
Insiders' Blog
Momentum Movers $
Options $
Special Reports
Trading Halts $
Trader Talk $
Offerings
Equity Offerings
IPOs $
Hot IPOs $
Other
Reuters
Contributors
General News
Life Enjoyed
Rating Changes
Analyst Comments $
Hot Comments $
Credit Ratings
Downgrades $
Hot Downgrades $
New Coverage $
Hot New Coverage $
Upgrades $
Hot Upgrades $
Unfiltered Feeds
Press Releases
SI Newswire
SEC Filings
Highlighted Articles
Goldman (GS), You're Doing it Wrong! Firm Looks to Expand Asset Management Division
New Highlighted Article
Most Analysts Call Amazon or Microsoft Bid for RIM 'Unlikely' (RIMM) (AMZN) (MSFT)
Send to a Friend
Font Size:
Increase
Decrease
Needham & Company
Login to help us fill in information about this entity.
Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); Q3 Review
Nov 2, 2011 08:20AM
Needham & Company Maintains a 'Buy' on Lexicon Pharmaceuticals (LXRX); Underappreciated Given Number of Phase 2 Compounds Under Development
Sep 22, 2011 02:23PM
Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); Encouraging Phase 2 LX1032 Results in Sandostatin-Treated Carcinoid Syndrome Patients
Aug 10, 2011 08:25AM
Needham & Company Starts Lexicon Pharmaceuticals (LXRX) at Buy; Valuation is Attractive
May 27, 2011 07:45AM
